Expanded Khorana risk score
| . | Risk score . |
|---|---|
| Cancer type | |
| Very high risk: brain, pancreatic, gastric | 2 |
| High risk: lung, lymphoma, gynecologic, bladder, testicular, myeloma, kidney | 1 |
| Hematological markers | |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin count <100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Patient factor | |
| Body mass index ≥35 kg/m2 | 1 |
| Procoagulant markers | |
| D-dimer ≥ 1.44 μg/mL | 1 |
| Soluble P-selectin ≥ 53.1 ng/mL | 1 |
| . | Risk score . |
|---|---|
| Cancer type | |
| Very high risk: brain, pancreatic, gastric | 2 |
| High risk: lung, lymphoma, gynecologic, bladder, testicular, myeloma, kidney | 1 |
| Hematological markers | |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin count <100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Patient factor | |
| Body mass index ≥35 kg/m2 | 1 |
| Procoagulant markers | |
| D-dimer ≥ 1.44 μg/mL | 1 |
| Soluble P-selectin ≥ 53.1 ng/mL | 1 |
Adapted from Ay et al.22